Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions

OBJECTIVE: Progression-free survival is an established clinically meaningful endpoint in ovarian cancer trials, but it may be susceptible to bias; therefore, blinded independent centralized radiological review is often included in trial designs. We compared blinded independent centralized review and...

Descripción completa

Detalles Bibliográficos
Autores principales: Herzog, Thomas J, Wahab, Shaun A, Mirza, Mansoor R, Pothuri, Bhavana, Vergote, Ignace, Graybill, Whitney S, Malinowska, Izabela A, York, Whitney, Hurteau, Jean A, Gupta, Divya, González-Martin, Antonio, Monk, Bradley J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646892/
https://www.ncbi.nlm.nih.gov/pubmed/37931976
http://dx.doi.org/10.1136/ijgc-2023-004605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646892/
https://www.ncbi.nlm.nih.gov/pubmed/37931976
http://dx.doi.org/10.1136/ijgc-2023-004605

Ejemplares similares